Oncimmune Holdings plc (LON: ONC), a leader in the development, manufacture and commercialisation of personalised immunodiagnostics for the screening, detection and care of cancer, will today be hosting a science day for analysts and investors at the Royal Institution, 21 Albemarle Street, London. The event will commence at 3pm GMT followed by a reception at 5.30pm GMT. No new price sensitive information will be disclosed.
The afternoon will feature presentations from Dr. Adam Hill, Chief Executive of Oncimmune; Professor Peter Johnson, Director of the Southampton Cancer Research UK Centre; Professor Tariq Sethi, Vice President AstraZeneca RIA TMU and Emeritus Professor of Respiratory Medicine Kings College London; Professor Frank Sullivan, Professor of Primary Care Medicine at the University of St. Andrews; Dr. Cheung To, Co-founder and Chairman of Gene Group Co. Ltd.; and Dr. Andrea Murray Chief Operational Scientist of Oncimmune. In addition, Oncimmune’s Board of Directors and members of its newly formed Scientific Board will be in attendance.
Discussion topics will include stratified cancer care based on tumour characteristics and the tumour micro environment focusing on the role of autoantibodies; opportunities for collaboration and partnerships between Chinese and UK companies arising out of the China Precision Medicine Initiative and the experiences of two companies forging a successful partnership; delayed presentation of cancers in primary care and the Early Detection of Cancer of the Lung, Scotland (ECLS) trial which will report in April 2019.
Agenda
15:00 Welcome by Meinhard Schmidt, Chairman
15:10 Introduction by Dr. Adam Hill, CEO
15:30 Immunology of Cancer – Professor Peter Johnson
15:50 Stratified Medicine and Cancer Care – Professor Tariq Sethi
16:10 Cancer Detection in Primary Care – Professor Frank Sullivan
16:30 The Opportunity in China – Dr. Cheung To & Dr. Andrea Murray
16:50 Thanks – Dr. Adam Hill, CEO
17:00 Q&A
17:30 Networking drinks and canapes
For further information or to register for the event, please contact Consilium Strategic Communications on oncimmune@consilium-comms.com or +44 (0) 203 709 5700.
